Nivagen Pharmaceuticals, marketing pharmaceuticals.#Marketing #pharmaceuticals

Posted On May 3 2018 by

Growth through Global Partnerships Product Development / Co-Development Model Nivagen’s business model is to identify and utilize the world`s best and economical CROs and CRAMs to develop and manufacture niche generic and OTC products. Acquisition and Licensing Model The US generic market is large and growing. The market is complex and fragmented and requires a variety of infrastructures to reach all major channels and segments. Partnerships Every business has its individual core strengths. One of Nivagen’s core strengths is the ability of our sales team to launch new generic products in the US market. Welcome to Nivagen Pharmaceuticals Nivagen is …

Cipher Pharmaceuticals Announces Beteflam Patch Accepted For Review By Health Canada, cipher pharmaceuticals.#Cipher #pharmaceuticals

Posted On Apr 23 2018 by

Cipher Pharmaceuticals Announces Beteflam Patch Accepted For Review By Health Canada MISSISSAUGA, ON , Feb. 12, 2015 /PRNewswire/ – Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) (“Cipher” or “the Company”) today announced that the Beteflam Patch (previously called the Betesil Patch) has been accepted for review by Health Canada. The Beteflam Patch is a novel, patent-protected, self-adhesive medicated plaster containing 0.1% betamethasone valerate, for the treatment of inflammatory skin conditions such as chronic plaque psoriasis (“CPP”). Topical corticosteroids remain the primary treatment for steroid-responsive inflammatory skin diseases, including mild to moderate CPP. Occlusion with plastic film dressings is a widely accepted …

Addex Therapeutics: about addex, addex pharmaceuticals.#Addex #pharmaceuticals

Posted On Apr 23 2018 by

addex pharmaceuticals allosteric modulators for human health Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Addex lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase IIa POC in Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter Phase III for PD-LID with support from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). In parallel, dipraglurant’s therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex second clinical program, ADX71149 (mGluR2 positive …

Today s Stock Market News and Analysis, lotus pharmaceuticals.#Lotus #pharmaceuticals

Posted On Apr 23 2018 by

Today’s Stock Market News Analysis In my own former narrow way of thinking I conceived of entrepreneurship as strictly a money thing and not Read Full Story Latest News Browse News by Category Technology Commodities Investing ideas Market Intelligence Stay ahead of the markets with these must-read articles Stock Market Today Stocks to Watch Careful What You Wish For? Dow Gains 120 Points, Tech Bounces Back as Tax Reform Looms Featured Story from Latest Articles by Martin Tillier Martin Tiller’s new must-read column on the markets Enlightening. Entertaining. Every day. Only at Edit Favorites Enter up to 25 symbols …

Unnati Pharmaceuticals Pvt, elder pharmaceuticals.#Elder #pharmaceuticals

Posted On Apr 23 2018 by

elder pharmaceuticals Call us: +91-22-6138 2222 | E-mail: [email protected] Iron Sucrose 5% Pyrogene Free Timolol Maleate Triclosan Ketoconazole Mirtazapine Baclofen Sodium Pico Sulphate Betacarotene 10% / 20% / 30% Nitazoxanide Lycopene Fluconazole Foundation Founder of our Organisation Late Shri Bhupatrai C Mehta had started a trading house with Four Principles derived from Four essentials of Life. Mr. Hetal Mehta, followed his principles and with the guidance of his elder brother Mr. Hemal Mehta. Expansion Now has come a long way of 20 years into pharmaceutical industry & transformed the company from a trading house to a Marketing Company serving as …

Group Sailing aboard the Schooner Woodwind in Annapolis, Maryland, middlebrook pharmaceuticals.#Middlebrook #pharmaceuticals

Posted On Apr 23 2018 by

Group Sailing We had a wonderful time aboard the Woodwind. Our family truly enjoyed the sail. We loved the fact that you used the guests to raise the sails, let us steer the boat and had so much interesting information regarding sailing and the sea. The crew was so friendly and made the day feel like we were out sailing with just old friends. We had such a great time! We had beautiful weather, calm seas, and lots of fun with the Captain and the entertainment. They both were so funny! Thanks again. Schooner Woodwind offers Group Sailing for groups …

Unichem Laboratories, unichem pharmaceuticals.#Unichem #pharmaceuticals

Posted On Apr 23 2018 by

Caring and Curing for over 7 decades Centre of Excellence (R width: 250px; margin: 0 10px 5px 0;” src=”” /> Marketed Products

Eagle Pharmaceuticals Receives Tentative FDA Approval for PEMFEXY (Pemetrexed Injection) Ready-to-Dilute, Eagle Pharmaceuticals Investor Center, eagle pharmaceuticals inc.#Eagle #pharmaceuticals #inc

Posted On Apr 19 2018 by

Investors Dateline: WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or “the Company”) today announced that the United States Food and Drug Administration (“FDA”) has granted tentative approval for the Company’s PEMFEXY™, a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or …

Unichem to return 50% of proceeds from Torrent deal to shareholders, unichem pharmaceuticals.#Unichem #pharmaceuticals

Posted On Apr 19 2018 by

Unichem to return 50% of proceeds from Torrent deal to shareholders Mumbai: Unichem Laboratories Ltd plans to return to its shareholders more than 50% of net proceeds it will receive from the sale of domestic formulations business to Torrent Pharmaceuticals Ltd. It will use the rest to expand its international business, particularly in the US. Post-tax, whatever funds we get from the Torrent deal will remain in the company. There are only two things we will do. One is that we want to return more than 50% to shareholders by way of enhanced dividend or buyback, and the other is …

Cetaphil brand allergy free rated skin products and ingredients, medicis pharmaceuticals.#Medicis #pharmaceuticals

Posted On Apr 19 2018 by

Cetaphil 85 Products from Cetaphil Category SkinSAFE Filters Allergens Safety Concern Brand Cetaphil OTC / Rx All OTC Only Rx Only Follow us SkinSAFE Mobile App Find out more Copyright 2017 HER Inc. All Rights Reserved.